Similarly, the CHARM (Crohn’s Trial of The Fully Human Antibody Adalimumab for Remission Maintenance) study confirmed that ADA treatment is also effective in the treatment of CD; after 56 weeks of treatment, remission without glucocorticoids was observed in 29% of patients with ADA, with only 6% receiving a placebo (p < 0.001). The gene discussed is ADA; the disease is Cowden disease.